Compliance

Transparency Initiative

At Calea and Fresenius Kabi we care for the life of patients worldwide.  To fulfill our commitment to benefit critically and chronically ill patients, collaborating with physicians, hospitals and patient organisations is essential.  These partnerships are not only required to develop products that best meet clinical needs.  Healthcare Professionals are provided with the necessary expertise and education to be able to safely and effectively use our drugs and medical devices.  In supporting medical research and education Fresenius Kabi contributes to patient safety and increased access to new technologies and services.

We expect transparency, accountability and high ethical standards from ourselves – and our stakeholders expect the same from us.  Their trust is rewarded by acting with utmost integrity and responsibility.  We believe that transparency is key to safeguard the integrity of these partnerships to the public and remain trusted.

Being member of various industry associations in the countries we are operating in, we have committed ourselves to disclose certain value transfers to Healthcare Professionals, Healthcare Organisations and selected patient care organisations in these countries.

In each such interaction, we respect the obligation of Healthcare Professionals to make independent treatment decisions.

We welcome any questions or remarks at transparency@fresenius-kabi.com

Carbon Reduction Plan 2022

Supplier name: Calea UK Limited, United Kingdom (UK)

Publication date: 19 April 2022

Overview

The UK Government amended the Climate Change Act 2008 in 2019 introducing a target of at least a 100% reduction in the net carbon account (reduction of greenhouse gas emissions compared to 1990 levels) by 2050.  This is the Net Zero Target.

FHC (Holdings) Limited is the holding company of two UK subsidiaries: Fresenius Kabi Limited and Calea UK Limited (together Fresenius Kabi UK).  These companies are healthcare companies involved in supplying pharmaceutical products, controlled drugs, medical devices, nutritional feed and nursing services. Both companies operate out of adjacent sites in Runcorn; these consist of warehouse space, offices, and an aseptic compounding centre.

Fresenius Kabi UK takes its responsibility to protect the environment seriously. We constantly work to improve our environmental protection efforts and apply high environmental standards in a bid to reduce greenhouse gas emissions in the UK. Furthermore, Fresenius Kabi UK is in full support of the Net Zero strategies in place across NHS England, NHS Scotland and NHS Wales.

Fresenius Kabi Limited is classified as a large unquoted UK company under the definition of the Streamlined Energy and Carbon Reporting regulations (SECR) by virtue of meeting both financial and employee thresholds.

Fresenius Kabi Limited reports its scope 1 and scope 2 emissions under the SECR. This plan covers all scope 1 and 2 emissions in line with the GHG Protocol Corporate Standard and Action Note PPN 06/21.  Work is currently being done to map scope 3 emissions and an interim report will follow.

To read the full UK Carbon Reduction Plan click here

HPN and Immunotherapy Homecare team call: 0800 121 8300
Biosimilars Homecare team call: 0800 090 2461